Despite their advantages, HepG2 cells have limitations. They originate from a cancerous liver and thus may not perfectly mimic normal liver physiology. Their expression levels of certain drug-metabolizing enzymes can be lower than those in primary hepatocytes, which might affect the accuracy of toxicity predictions. Additionally, these cells do not have the three-dimensional architecture of liver tissue, which can influence drug metabolism and toxicity.
